Simona Moffa

Simona Moffa

Auto-generated profile, based on publicly available information

Simona Moffa

Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario A Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
FCFrancesca Cinti
Francesca Cinti
SMSimona Moffa
Simona Moffa
FIFlavia Impronta
Flavia Impronta
CCChiara Maria Assunta Cefalo
Chiara Maria Assunta Cefalo
VSVinsin Alice Sun
Vinsin Alice Sun
AGAndrea Giaccari
Andrea Giaccari
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the latest therapeutic strategy in the treatment of type 2 diabetes mellitus (T2DM). Using an insulin-independent mechanism (glycosuria), they reduce glucose toxicity and improve insulin sensitivity and β-cell function. The promising results obtained in clinical trials show that SGLT2 significantly improves glycemic control and provides greater cardiovascular protection, combined with a reduction in body weight and blood pressure (BP). This review focuses on ertugliflozin, a new, highly selective, and reversible SGLT2 inhibitor. Clinical trials published to date show that ertugliflozin, both as a monotherapy and as an add-on to oral antidiabetic agents, is safe and effective in reducing glycosylated hemoglobin (HbA1c), body weight, and BP in T2DM patients.